↑ 疾患リストへ ← 戻る

 127. 前頭側頭葉変性症 [臨床試験数:44,薬物数:54(DrugBank:21),標的遺伝子数:24,標的パスウェイ数:46] 

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03987295September 27, 20194 November 2019A Study to Evaluate Safety of Long-term AL001 Dosing in FTD PatientsA Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal DementiaFrontotemporal DementiaDrug: AL001Alector Inc.Recruiting18 Years80 YearsAll32Phase 2United States;Canada;Germany;Italy;Netherlands;United Kingdom
2NCT04115384September 9, 201914 October 2019Intranasal Insulin in Frontotemporal Dementia (FTD)A Single Center Feasibility Study of Intranasal Insulin in Frontotemporal Dementia NIFT-DFrontotemporal Dementia, Behavioral VariantDrug: Novolin-R insulinHealthPartners InstituteRecruiting41 Years89 YearsAll12Phase 2United States
3NCT03636204September 14, 201829 April 2019A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin MutationA First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin MutationHealthy;Frontotemporal DementiaBiological: AL001;Other: PlaceboAlector Inc.Recruiting18 Years80 YearsAll60Phase 1United States;Canada;United Kingdom;Netherlands
4NCT03658135September 12, 201815 April 2019BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESA Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy SyndromesPrimary Tauopathies;Corticobasal Degeneration Syndrome;Frontotemporal Lobar Degeneration With Tau Inclusions;MAPT Mutation Carriers, Symptomatic;Traumatic Encephalopathy Syndrome;Nonfluent Aphasia, ProgressiveDrug: BIIB092;Other: PlaceboUniversity of California, San FranciscoRecruiting35 Years80 YearsAll32Phase 1United States
5NCT03260920January 31, 201811 February 2019Intranasal Oxytocin for Frontotemporal DementiaA Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal DementiaFrontotemporal DementiaDrug: SyntocinonLawson Health Research InstituteWeston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry ConsultantsRecruiting30 Years80 YearsAll112Phase 2United States;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03625128January 2, 201828 October 201918F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNot recruiting20 Years90 YearsAll36Early Phase 1Taiwan
7NCT02707978September 30, 20174 February 2019F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)F 18 T807 Tau PET Imaging of Frontotemporal DementiaAlzheimer DiseaseDrug: F 18 T807Washington University School of MedicineNot recruiting18 YearsN/AAll0Phase 2United States
8NCT03272230September 6, 20171 April 2019Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based SystemAssessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral DiseaseApathy;Frontotemporal Dementia;Parkinson Disease;Depressive SymptomsBehavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's DiseaseInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting40 Years85 YearsAll135N/AFrance
9NCT03545126August 21, 20177 October 2019Human CNS Tau Kinetics in TauopathiesHuman CNS Tau Kinetics in TauopathiesProgressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation)Other: 13C6 LeucineWashington University School of MedicineAssociation of Frontotemporal Degeneration;Tau ConsortiumRecruiting18 YearsN/AAll32N/AUnited States
10NCT03174938May 15, 201711 June 2018The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03040713April 11, 201721 January 2019Flortaucipir PET Imaging in Subjects With FTD18F-AV-1451 PET Imaging in Subjects With Frontotemporal DementiaFrontotemporal DementiaDrug: 18F-AV-1451;Drug: 18F-AV-45Avid RadiopharmaceuticalsNot recruiting18 YearsN/AAll14Phase 1United States
12EUCTR2017-000094-36-SE31/03/201722 May 2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disordersNeurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: HLGT Classification code 10028037 Term: Movement disorders (incl parkinsonism) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10048598 Term: Cognitive disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1 Level: PT Classification code 10074616 Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Pharmaceutical Form: Injection
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Pharmaceutical Form: Injection
Skåne University HospitalAuthorisedFemale: yes
Male: yes
Phase 2Sweden
13NCT02862210January 27, 201726 August 2019Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaLow-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaFrontotemporal Dementia (FTD)Drug: Lithium Carbonate;Drug: PlaceboColumbia UniversityAlzheimer’s Drug Discovery FoundationRecruiting40 Years85 YearsAll60Phase 2United States
14EUCTR2015-005604-29-NL16/11/20162 October 2017Imaging of tau in patients with dementiaTau-imaging in tauopathies; Alzheimer’s disease and non-AD dementias - TITANDementia inducing Alzheimer's disease, Frontotemporal dementia (FTD) and Lewy Body Dementia (DLB)
MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: LLT Classification code 10057095 Term: Diffuse Lewy body disease System Organ Class: 100000072901
MedDRA version: 20.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0 Level: LLT Classification code 10012283 Term: Dementia due to other general medical conditions System Organ Class: 100000014717 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: 18F-AV-1451
Pharmaceutical Form: Solution for injection
INN or Proposed INN: not applicable
CAS Number: 152201-90-6
Current Sponsor code: 18F-Av-1451
Other descriptive name: T807
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 240-
VU University Medical CenterAuthorisedFemale: yes
Male: yes
Phase 2Netherlands
15NCT02676843April 20168 April 2019Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsTau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsFrontotemporal Lobar Degeneration;FTLD;Frontotemporal Dementia;FTD;TauopathiesDrug: 18F-AV-1451Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll7Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2014-001315-40-IT03/12/201411 April 2016Florbetapir-PET scan in subjects with a known mutation for autosomal dominant Alzheimer's Disease taking part in the ItalianDIAfN studyAmyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)” - Amyloid-PET in ItalianDIAfNAutosomal Dominant Alzheimer's Disease
MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Amyvid
Product Name: Florbetapir (18F)
Product Code: Florbetapir (18F)
Pharmaceutical Form: Injection
INN or Proposed INN: florbetapir (18F)
CAS Number: 956103-76-7
Current Sponsor code: N/A
Other descriptive name: N/A
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 370-
IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliAuthorisedFemale: yes
Male: yes
Italy
17EUCTR2014-002013-37-GB06/10/20148 August 2016An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAn Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal DementiaAlzheimer’s Disease and behavioral variant Frontotemporal Dementia
MedDRA version: 19.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
Pharmaceutical Form: Tablet
INN or Proposed INN: N/A
CAS Number: 1236208-20-0
Current Sponsor code: TRx0237
Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
TauRx Therapeutics LtdAuthorisedFemale: yes
Male: yes
966Phase 3United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
18NCT02149160October 201411 April 2016Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationGranulin MutationDrug: FRM-0334;Drug: PlaceboFORUM Pharmaceuticals IncNot recruiting21 Years75 YearsBoth30Phase 2United States;Belgium;France;Italy;Netherlands;United Kingdom
19EUCTR2014-000422-38-SE19/09/20147 October 2014A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tauAn open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tauNeurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions.
MedDRA version: 17.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-AV-1451
Pharmaceutical Form: Injection
Skåne University Hospital, Region SkåneAuthorisedFemale: yes
Male: yes
Sweden
20NCT02245568August 201411 June 2018Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)Alzheimer's Disease;Behavioral Variant Frontotemporal DementiaDrug: TRx0237TauRx Therapeutics LtdNot recruitingN/AN/AAll913Phase 3United States;Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Argentina;Bulgaria;Italy;Poland;Romania
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT01937013September 12, 201320 August 2018Impact of Emotional Mimicry and Oxytocin on Frontotemporal DementiaImpact of Emotional Mimicry and Oxytocin on Frontotemporal DementiaFrontotemporal DementiaDrug: Intranasal oxytocin;Drug: Saline Nasal MistLawson Health Research InstituteCanadian Institutes of Health Research (CIHR)Not recruiting30 Years85 YearsAll52Phase 2Canada
22NCT01626378May 201311 June 2018Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)Behavioral Variant Frontotemporal Dementia (bvFTD)Drug: TRx0237;Drug: PlaceboTauRx Therapeutics LtdNot recruitingN/A79 YearsAll220Phase 3United States;Australia;Canada;Croatia;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;Argentina;Bulgaria;Finland
23EUCTR2012-004328-40-IT01/03/201327 January 2014study of neuroinflammation in pathologies like Alzheimer, mild cognitive impairment, dementia and SLAIMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASESmild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
MedDRA version: 14.1 Level: LLT Classification code 10050727 Term: RI scan System Organ Class: 100000004848 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: NA
Product Code: (R)-[N-metil-11C1-PK11195(PK)
Pharmaceutical Form: Solution for injection
Current Sponsor code: (R)-[N-metil-11C]-PK11195
Concentration unit: MBq megabecquerel(s)
Concentration type: up to
Concentration number: 185-
OSPEDALE S. RAFFAELE DI MILANOAuthorisedFemale: yes
Male: yes
Italy
24EUCTR2011-005529-34-GB17/01/201328 September 2015A comparison study of LMTM and placebo in patients with behavioral variant frontotemporal dementiaA Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) - TRx-237-007behavioral variant Frontotemporal Dementia (bvFTD)
MedDRA version: 18.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
Pharmaceutical Form: Tablet
INN or Proposed INN: N/A
CAS Number: 1236208-20-0
Current Sponsor code: TRx0237
Other descriptive name: N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
TauRx Therapeutics LtdAuthorisedFemale: yes
Male: yes
180United States;Finland;Spain;United Kingdom;Italy;Canada;Poland;Singapore;Croatia;Romania;Australia;Germany;Netherlands
25EUCTR2011-005529-34-DE28/12/201230 May 2016A comparison study of LMTM and placebo in patients with behavioral variant frontotemporal dementiaA Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) - TRx-237-007behavioral variant Frontotemporal Dementia (bvFTD)
MedDRA version: 18.1 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Leuco-methylthioninium bis(hydromethanesulfonate)
Product Code: LMTM/TRx0237
Pharmaceutical Form: Tablet
INN or Proposed INN: N/A
CAS Number: 1236208-20-0
Current Sponsor code: TRx0237
Other descriptive name: N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
TauRx Therapeutics LtdNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Finland;Spain;United Kingdom;Italy;Canada;Poland;Singapore;Croatia;Romania;Australia;Germany;Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2011-004571-37-IT21/02/201223 May 2012Amiodarone therapy for treatment of fontotemporat dementia caused by progranulin deficiency- Rescue of Progranulin HaploInsufficiency in Frontotemporal Dementia - ReProIn-FTDfrontotemporal dementia associated to progranulin deficit
MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Pharmaceutical Form: Tablet
INN or Proposed INN: AMIODARONE
CAS Number: 1951-25-3
Current Sponsor code: NA
Other descriptive name: NA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIAAuthorisedFemale: yes
Male: yes
Italy
27NCT00604591July 201126 August 2019Effects of Tolcapone on Frontotemporal DementiaInvestigation of the Dopamine System in Frontotemporal DementiaFrontotemporal Lobar DegenerationDrug: Tolcapone;Drug: PlaceboColumbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting40 Years85 YearsAll28Phase 2United States
28NCT01386333June 201119 February 2015Safety Study of Intranasal Oxytocin in Frontotemporal DementiaA Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EFFrontotemporal DementiaDrug: oxytocin;Drug: Saline Nasal MistLawson Health Research InstituteThe Consortium of Canadian Centres for Clinical Cognitive Research (C5R)Not recruiting30 Years80 YearsBoth23Phase 1Canada
29JPRN-UMIN0000036832010/06/012 April 2019The efficacy of ferulic acid in the treatment of dementiaAlzheimer's Disease, Dementia of Lewy Body,Vascular Dementia, Frontotemporal DementiaTaking of Ferulic Acid for 6 months followed by Not taking of Ferulic Acid for 6 months.

Not taking of Ferulic Acid for 6 months followed by taking of Ferulic Acid for 6 months.
Shimane University HospitalNot Recruiting20years-old90years-oldMale and Female50Not selectedJapan
30NCT01623284March 20104 January 2016PiB PET Scanning in Speech and Language Based DementiasPiB PET Scanning in Speech and Language Based DementiasPPA;Primary Progressive Aphasia;Aphasia;Non-fluent Aphasia;Semantic Dementia;Apraxia of Speech;Primary Progressive Nonfluent Aphasia;Progressive AphasiaDrug: C-11 PiB;Drug: F-18 FDGMayo ClinicNot recruiting18 YearsN/ABoth168Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01056965January 201015 April 2019Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyA 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted TauopathiesPredicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent AphasiaDrug: davunetide (AL-108, NAP);Drug: Placebo nasal sprayUniversity of California, San FranciscoNot recruiting40 Years85 YearsAll12Phase 1United States
32NCT01002300September 200919 February 2015Oxytocin and Social Cognition in Frontotemporal DementiaInvestigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal DementiaFrontotemporal Dementia;Pick's DiseaseDrug: intranasal oxytocinLawson Health Research InstituteThe Alzheimer Society London and MiddlesexNot recruiting30 Years80 YearsBoth24N/ACanada
33NCT01890343September 200919 October 2017Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.Alzheimer's Disease;Frontotemporal DementiaDrug: florbetapir 18F;Drug: 18F-FDGAvid RadiopharmaceuticalsNot recruiting45 YearsN/AAll34Phase 2United Kingdom
34EUCTR2008-003597-18-GB28/05/200919 March 2012Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersA study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controlsUse of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.
MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - Investigations
Product Name: florbetapir 18F
Product Code: 18F-AV-45
Pharmaceutical Form: Injection
CAS Number: 956103-76-7
Current Sponsor code: 18F-AV-45
Other descriptive name: florbetapir 18F Injection
Concentration unit: MBq/µl megabecquerel(s)/microlitre
Concentration type: not less then
Concentration number: 54-
Avid Radiopharmaceuticals, IncAuthorisedFemale: yes
Male: yes
40United Kingdom
35NCT00950430April 200814 October 2019Imaging of Brain Amyloid Plaques in the Aging PopulationBrain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Frontotemporal Dementia;Vascular DementiaDrug: Pittsburgh Compound B (C-11 PiB);Drug: F-18 FDG;Drug: Tau (18-F-AV-1451)Mayo ClinicNational Institute on Aging (NIA)Recruiting30 Years100 YearsAll2500Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36JPRN-UMIN0000032392008/01/012 April 2019Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementiaFrontotemporal dementiaDiscontinuation of donepezilNational Hospital Organization Kikuchi HospitalNot Recruiting50years-old90years-oldMale and Female25Not selectedJapan
37NCT00545974October 200722 October 2019Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal DementiaA Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal DementiaFrontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic DementiaDrug: memantine;Drug: Placebo pillUniversity of California, San FranciscoForest LaboratoriesNot recruiting40 Years80 YearsAll81Phase 4United States
38NCT00594737October 200719 February 2015Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal DementiaAn Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal DementiaFrontotemporal DementiaDrug: memantine hydrochlorideTiffany Chow, MDH. Lundbeck A/SNot recruiting40 Years80 YearsBoth17Phase 3Canada
39NCT00376051September 200616 December 2017Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaSerotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaFrontotemporal DementiaDrug: CitalopramSunnybrook Health Sciences CentreAlzheimer Society of CanadaNot recruiting18 YearsN/AAll22Phase 4Canada
40EUCTR2005-005915-13-GB12/07/200614 August 2012An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromesAn Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromesFrontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potential for slowing the disease process as well as providing symptomatic improvement in hitherto untreatable, ultimately fatal conditions.
MedDRA version: 8.1 Level: PT Classification code 10012267
Product Name: Methylthioninium chloride
Product Code: MTC TRx0014-001 capsules
Pharmaceutical Form: Capsule, hard
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100 -
TauRx Therapeutics PTE LtdAuthorisedFemale: yes
Male: yes
20United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT00127114September 200516 December 2017Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)DementiaDrug: Amantadine;Drug: PlaceboJohns Hopkins UniversityNot recruiting40 Years90 YearsAll0Phase 4United States
42NCT00200538September 200519 February 2015Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) PatientsDouble-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) PatientsDementiaDrug: memantineNantes University HospitalNot recruiting45 Years75 YearsBoth52Phase 2France
43NCT00187525May 200419 February 2015A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar DegenerationFrontotemporal Lobar DegenerationDrug: MemantineUniversity of California, San FranciscoForest LaboratoriesNot recruiting40 Years80 YearsBothPhase 4
44NCT00416169May 200319 February 2015A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal DementiaAn Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick ComplexFrontotemporal Dementia;Pick ComplexDrug: galantamine hydrobromideJohnson & Johnson Pharmaceutical Research & Development, L.L.C.Not recruiting30 Years80 YearsBoth41Phase 2

先頭へ